The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy
Open accessAbstract
Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and overall prognosis. The pathogenesis is complex and typically multifactorial, with iron deficiency (ID) often being a major and potentially treatable contributor. In turn, ID in cancer patients can be due to multiple concurring mechanisms, including bleeding (e.g., in gastrointestinal cancers or after surgery), malnutrition, medications, and hepcidin-driven iron sequestration into macrophages with subsequent iron-restricted erythropoiesis. Indeed, either absolute or functional iron deficiency (AID or FID) can occur. While for absolute ID there is a general consensus regarding the laboratory definition (that is ferritin levels <100 ng/mL ± transferrin saturation (TSAT) <20%), a shared definition of functional ID is still lacking. Current therapeutic options in cancer anemia include iron replacement, erythropoietic stimulating agents (ESAs), and blood transfusions. The latter should be kept to a minimum, because of concerns regarding risks, costs, and limited resources. Iron therapy has proved to be a valid approach to enhance efficacy of ESAs and to reduce transfusion need. Available guidelines focus mainly on patients with chemotherapy-associated anemia, and generally suggest intravenous (IV) iron when AID or FID is present. However, in the case of FID, the upper limit of ferritin in association with TSAT <20% at which iron should be prescribed is a matter of controversy, ranging up to 800 ng/mL. An increasingly recognized indication to IV iron in cancer patients is represented by preoperative anemia in elective oncologic surgery. In this setting, the primary goal of treatment is to decrease the need of blood transfusions in the perioperative period, rather than improving anemia-related symptoms as in chemotherapy-associated anemia. Protocols are mainly based on experiences of Patient Blood Management (PBM) in non-oncologic surgery, but no specific guidelines are available for oncologic surgery. Here we discuss some possible approaches to the management of ID in cancer patients in different clinical settings, based on current guidelines and recommendations, emphasizing the need for further research in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“, IL-6, IL-1, TNF-α, and interferon-γ), that upregulate hepcidin synthesis in the liver [48,49].”
BackgroundIron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
HIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
Knight, K., Wade, S., & Balducci, L. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.008 · Cited by 878
Iron homeostasis in host defence and inflammation
Ganz, T., & Nemeth, E. (2015) · Nature Reviews Immunology · doi:10.1038/nri3863 · Cited by 843 · cited 1×
“, IL-6, IL-1, TNF-α, and interferon-γ), that upregulate hepcidin synthesis in the liver [48,49].”
BackgroundIron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507 · cited 1×
“Data from epidemiological studies and animal models have raised some concerns regarding the possible role of deregulated iron metabolism in certain cancer types [96,97], including promotion of tumor growth and enhanced oxidative stress [98].”
BackgroundCappellini, M. D., Comin‐Colet, J., de Francisco, A., Dignass, A., Doehner, W., Lam, C. S., Macdougall, I. C., Rogler, G., Camaschella, C., Kadir, R., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24820 · Cited by 502
Hepcidin in the diagnosis of iron disorders
Girelli, D., Nemeth, E., & Swinkels, D. W. (2016) · Blood · doi:10.1182/blood-2015-12-639112 · Cited by 417
Self-citationDetection, evaluation, and management of iron-restricted erythropoiesis
Goodnough, L. T., Nemeth, E., & Ganz, T. (2010) · Blood · doi:10.1182/blood-2010-05-286260 · Cited by 410
Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children
Prentice, A. M., Doherty, C. P., Abrams, S. A., Cox, S. E., Atkinson, S. H., Verhoef, H., Armitage, A. E., & Drakesmith, H. (2012) · Blood · doi:10.1182/blood-2011-11-391219 · Cited by 167
Iron and innate antimicrobial immunity-depriving the pathogen, defending the host
Nairz, M., Dichtl, S., Schroll, A., Haschka, D., Tymoszuk, P., Theurl, I., & Weiss, G. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.03.007 · Cited by 123
Serum Hepcidin in Inflammatory Bowel Diseases: Biological and Clinical Significance
Bergamaschi, G., Di Sabatino, A., Albertini, R., Costanzo, F., Guerci, M., Masotti, M., Pasini, A., Massari, A., Campostrini, N., Corbella, M., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829a6e43 · Cited by 56
Self-citation
Research works printed but not linked: 88
- Ludwig, 2004, The European cancer anaemia survey (ecas): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, Eur. J. Cancer, 40, 2293, 10.1016/j.ejca.2004.06.019 · DOI · Paper page
- Grotto, 2008, Anaemia of cancer: An overview of mechanisms involved in its pathogenesis, Med. Oncol., 25, 12, 10.1007/s12032-007-9000-8 · DOI
- Gilreath, 2014, Diagnosis and treatment of cancer-related anemia, Am. J. Hematol., 89, 203, 10.1002/ajh.23628 · DOI · Paper page
- Gaspar, 2015, Anemia in malignancies: Pathogenetic and diagnostic considerations, Hematology, 20, 18, 10.1179/1607845414Y.0000000161 · DOI
- Adamson, 2008, The anemia of inflammation/malignancy: Mechanisms and management, Hematol. Am. Soc. Hematol. Educ. Program, 2008, 159, 10.1182/asheducation-2008.1.159 · DOI
- Rapoport, 2016, Current trends in the management of anaemia in solid tumours and haematological malignancies, Curr. Opin. Support Palliat. Care, 10, 189, 10.1097/SPC.0000000000000209 · DOI
- Harper, 2005, Anaemia of cancer: Impact on patient fatigue and long-term outcome, Oncology, 69, 2, 10.1159/000088282 · DOI
- Crawford, 2002, Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy, Cancer, 95, 888, 10.1002/cncr.10763 · DOI · Paper page
- Caro, 2001, Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review, Cancer, 91, 2214, 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P · DOI · Paper page
- Deeb, 2011, Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia, Leuk. Res., 35, 579, 10.1016/j.leukres.2010.10.020 · DOI
- Morine, 2011, Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma, Hepatogastroenterology, 58, 1439, 10.5754/hge11156 · DOI
- Zheng, S.S., Chen, X.H., Yin, X., and Zhang, B.H. (2013). Prognostic significance of hif-1alpha expression in hepatocellular carcinoma: A meta-analysis. PLoS ONE, 8. · DOI
- Harrison, 2002, Impact of tumor hypoxia and anemia on radiation therapy outcomes, Oncologist, 7, 492, 10.1634/theoncologist.7-6-492 · DOI · Paper page
- Vaupel, 2004, Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response, Oncologist, 9, 4, 10.1634/theoncologist.9-90005-4 · DOI · Paper page
- Cella, 2003, Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes, Ann. Oncol., 14, 511, 10.1093/annonc/mdg167 · DOI
- Calabrich, 2011, Management of anemia in cancer patients, Future Oncol., 7, 507, 10.2217/fon.11.24 · DOI
- Littlewood, 2001, Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial, J. Clin. Oncol., 19, 2865, 10.1200/JCO.2001.19.11.2865 · DOI · Paper page
- Cata, 2013, Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions, Br. J. Anaesth., 110, 690, 10.1093/bja/aet068 · DOI · Paper page
- Acheson, 2012, Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: A systematic review and meta-analysis, Ann. Surg., 256, 235, 10.1097/SLA.0b013e31825b35d5 · DOI · Paper page
- Liu, L., Wang, Z., Jiang, S., Shao, B., Liu, J., Zhang, S., Zhou, Y., Zhou, Y., and Zhang, Y. (2013). Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: A meta-analysis. PLoS ONE, 8. · DOI
- Luan, H., Ye, F., Wu, L., Zhou, Y., and Jiang, J. (2014). Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: A systematic review and a meta-analysis. BMC Surg., 14. · DOI
- Sun, 2015, Allogeneic blood transfusion and the prognosis of gastric cancer patients: Systematic review and meta-analysis, Int. J. Surg., 13, 102, 10.1016/j.ijsu.2014.11.044 · DOI
- Prescott, 2016, How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology, Cancer Treat Rev., 46, 1, 10.1016/j.ctrv.2016.03.010 · DOI
- Boone, 2014, Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients, Gynecol. Oncol., 132, 227, 10.1016/j.ygyno.2013.10.019 · doi:10.1016/j.ygyno.2013.10.019
- Alkhalid, 2017, Restrictive transfusion threshold is safe in high-risk patients undergoing brain tumor surgery, Clin. Neurol. Neurosurg., 163, 103, 10.1016/j.clineuro.2017.10.018 · DOI
- Vincent, 2015, Transfusion requirements in surgical oncology patients: A prospective, randomized controlled trial, Anesthesiology, 122, 29, 10.1097/ALN.0000000000000511 · DOI · Paper page
- Vansteenkiste, 2002, Darbepoetin alfa: Impact on treatment for chemotherapy-induced anemia and considerations in special populations, Oncology, 16, 45
- Hedenus, 2003, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study, Br. J. Haematol., 122, 394, 10.1046/j.1365-2141.2003.04448.x · doi:10.1046/j.1365-2141.2003.04448.x
- Bennett, 2008, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia, JAMA, 299, 914, 10.1001/jama.299.8.914 · DOI · Paper page
- Samaras, 2008, Risks of venous thromboembolism and mortality associated with erythropoiesis-stimulating agents for the treatment of cancer-associated anemia, Am. J. Hematol. Oncol., 7, 327
- Henke, 2003, Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial, Lancet, 362, 1255, 10.1016/S0140-6736(03)14567-9 · DOI · Paper page
- Wright, 2007, Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia, J. Clin. Oncol., 25, 1027, 10.1200/JCO.2006.07.1514 · DOI · Paper page
- Smith, 2008, Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study, J. Clin. Oncol., 26, 1040, 10.1200/JCO.2007.14.2885 · DOI · Paper page
- Farrell, 2004, The erythropoietin receptor and its expression in tumor cells and other tissues, Oncologist, 9, 18, 10.1634/theoncologist.9-90005-18 · DOI · Paper page
- Aapro, 2012, Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer, Br. J. Cancer, 106, 1249, 10.1038/bjc.2012.42 · DOI
- Aapro, 2015, Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: A meta-analysis, Ann. Oncol., 26, 688, 10.1093/annonc/mdu579 · doi:10.1093/annonc/mdu579
- Bennett, 2016, Consensus on the existence of functional erythropoietin receptors on cancer cells, JAMA Oncol., 2, 134, 10.1001/jamaoncol.2015.3940 · doi:10.1001/jamaoncol.2015.3940
- Glaspy, 2010, Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes, Br. J. Cancer, 102, 301, 10.1038/sj.bjc.6605498 · DOI · Paper page
- Ohashi, 2013, Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from japanese randomized, placebo-controlled trials, Cancer Sci., 104, 481, 10.1111/cas.12105 · doi:10.1111/cas.12105
- Rizzo, 2010, American society of hematology/american society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer, Blood, 116, 4045, 10.1182/blood-2010-08-300541 · DOI · Paper page
- Ludwig, 2013, Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia, Ann. Oncol., 24, 1886, 10.1093/annonc/mdt118 · DOI · Paper page
- Aapro, 2012, Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.V. Iron, Ann. Oncol., 23, 1954, 10.1093/annonc/mds112 · DOI · Paper page
- Ludwig, 2015, Iron metabolism and iron supplementation in cancer patients, Wien. Klin. Wochenschr., 127, 907, 10.1007/s00508-015-0842-3 · DOI
- Ueda, 2017, Role of hepcidin-25 in chronic kidney disease: Anemia and beyond, Curr. Med. Chem., 24, 1417, 10.2174/0929867324666170316120538 · doi:10.2174/0929867324666170316120538
- Ueda, N., and Takasawa, K. (2018). Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients, 10. · DOI · Paper page
- Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascon, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., and Ludwig, H. (2018). Management of anaemia and iron deficiency in patients with cancer: Esmo clinical practice guidelines. Ann. Oncol. · DOI
- Anand, 2018, Anemia and iron deficiency in heart failure: Current concepts and emerging therapies, Circulation, 138, 80, 10.1161/CIRCULATIONAHA.118.030099 · DOI · Paper page
- Steinmetz, 2013, Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia, Ann. Oncol., 24, 475, 10.1093/annonc/mds338 · DOI
- Verhaeghe, 2017, The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study, Ann. Gastroenterol., 30, 654
- Pfeiffer, 2017, Laboratory methodologies for indicators of iron status: Strengths, limitations, and analytical challenges, Am. J. Clin. Nutr., 106, 1606S, 10.3945/ajcn.117.155887 · DOI · Paper page
- Theurl, 2009, Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications, Blood, 113, 5277, 10.1182/blood-2008-12-195651 · DOI · Paper page
- Laarakkers, 2011, Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia, Arthritis Rheum., 63, 3672, 10.1002/art.30623 · DOI
- Shu, 2015, Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: Pathogenic mechanisms and diagnosis, Eur. J. Haematol., 94, 67, 10.1111/ejh.12402 · DOI
- Steensma, 2015, Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia, Blood, 125, 3669, 10.1182/blood-2015-03-636407 · DOI
- Hendriks, 2016, Toward worldwide hepcidin assay harmonization: Identification of a commutable secondary reference material, Clin. Chem., 62, 993, 10.1373/clinchem.2016.256768 · DOI
- Auerbach, 2004, Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial, J. Clin. Oncol., 22, 1301, 10.1200/JCO.2004.08.119 · DOI · Paper page
- Hedenus, 2007, Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study, Leukemia, 21, 627, 10.1038/sj.leu.2404562 · DOI · Paper page
- Henry, 2007, Epoetin alfa treatment for patients with chemotherapy-induced anemia, Support Cancer Ther., 4, 78, 10.3816/SCT.2007.n.002 · doi:10.3816/sct.2007.n.002
- Bastit, 2008, Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, J. Clin. Oncol., 26, 1611, 10.1200/JCO.2006.10.4620 · DOI · Paper page
- Pedrazzoli, 2008, Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha, J. Clin. Oncol., 26, 1619, 10.1200/JCO.2007.12.2051 · DOI · Paper page
- Auerbach, 2010, Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, Am. J. Hematol., 85, 655, 10.1002/ajh.21779 · DOI
- Mhaskar, 2016, The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents, Cochrane Database Syst. Rev., 2, CD009624
- Vidal, 2013, Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—Systematic review and meta-analysis of randomised controlled trials, Acta Oncol., 52, 18, 10.3109/0284186X.2012.702921 · DOI
- Petrelli, 2012, Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials, J. Cancer Res. Clin. Oncol., 138, 179, 10.1007/s00432-011-1072-3 · DOI
- Girelli, 2018, Modern iron replacement therapy: Clinical and pathophysiological insights, Int. J. Hematol., 107, 16, 10.1007/s12185-017-2373-3 · DOI · Paper page
- Kim, 2007, Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy, Gynecol. Oncol., 105, 199, 10.1016/j.ygyno.2006.11.014 · DOI
- Dangsuwan, 2010, Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy, Gynecol. Oncol., 116, 522, 10.1016/j.ygyno.2009.12.004 · DOI
- Athibovonsuk, 2013, Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy, Gynecol. Oncol., 131, 679, 10.1016/j.ygyno.2013.09.028 · DOI
- Hedenus, 2014, Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy, Med. Oncol., 31, 302, 10.1007/s12032-014-0302-3 · DOI
- Coussirou, 2018, Impact of ferric carboxymaltose on the evolution of hemoglobin and ecog performance status in iron-deficient patients with solid tumors: A 3-month follow-up retrospective study, Support Care Cancer, 26, 3827, 10.1007/s00520-018-4250-x · DOI
- Clevenger, 2015, Patient blood management to reduce surgical risk, Br. J. Surg., 102, 1325, 10.1002/bjs.9898 · DOI
- Munoz, 2015, Pre-operative anaemia: Prevalence, consequences and approaches to management, Blood Transfus., 13, 370
- Rineau, 2016, Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: A before-after study, Transfusion, 56, 673, 10.1111/trf.13468 · DOI
- Yoo, 2011, Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery, Anesthesiology, 115, 929, 10.1097/ALN.0b013e318232004b · doi:10.1097/aln.0b013e318232004b
- Ecker, 2016, Blood transfusion in major abdominal surgery for malignant tumors: A trend analysis using the national surgical quality improvement program, JAMA Surg., 151, 518, 10.1001/jamasurg.2015.5094 · DOI
- Dixon, 2009, Blood loss in surgical oncology: Neglected quality indicator?, J. Surg. Oncol., 99, 508, 10.1002/jso.21187 · DOI
- Keding, 2018, Patient blood management improves outcome in oncologic surgery, World J. Surg. Oncol., 16, 159, 10.1186/s12957-018-1456-9 · DOI
- Borstlap, 2015, Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: A systematic review, Colorectal Dis., 17, 1044, 10.1111/codi.13110 · DOI
- Keeler, 2014, The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer, Colorectal Dis., 16, 794, 10.1111/codi.12683 · DOI
- Edwards, 2009, Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery, Br. J. Surg., 96, 1122, 10.1002/bjs.6688 · DOI
- Lidder, 2007, Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery—A prospective, randomised, controlled trial, Ann. R. Coll. Surg. Engl., 89, 418, 10.1308/003588407X183364 · doi:10.1308/003588407x183364
- Calleja, 2016, Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia, Int. J. Colorectal Dis., 31, 543, 10.1007/s00384-015-2461-x · DOI
- Froessler, 2016, The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: A randomized controlled trial, Ann. Surg., 264, 41, 10.1097/SLA.0000000000001646 · DOI · Paper page
- Gilreath, 2012, Total dose iron dextran infusion in cancer patients: Is it safe2+?, J. Natl. Compr. Cancer Netw., 10, 669, 10.6004/jnccn.2012.0066 · DOI
- Beguin, 2014, Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis—A critical review, Crit. Rev. Oncol. Hematol., 89, 1, 10.1016/j.critrevonc.2013.10.008 · DOI
- Jaspers, 2015, Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival, Am. J. Hematol., 90, E197, 10.1002/ajh.24100 · doi:10.1002/ajh.24100
- Wilson, 2018, The effect of intravenous iron therapy on long-term survival in anaemic colorectal cancer patients: Results from a matched cohort study, Surg. Oncol., 27, 192, 10.1016/j.suronc.2018.03.005 · DOI
- Busti, 2014, Iron deficiency in the elderly population, revisited in the hepcidin era, Front. Pharmacol., 5, 83, 10.3389/fphar.2014.00083 · DOI
Cited by
Wang, Y., Yu, L., Ding, J., & Chen, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010095 · Cited by 294
Why cells need iron: a compendium of iron utilisation
Teh, M. R., Armitage, A. E., & Drakesmith, H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.04.015 · Cited by 114
Oliero, M., Calvé, A., Fragoso, G., Cuisiniere, T., Hajjar, R., Dobrindt, U., & Santos, M. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-07876-8 · Cited by 47
Metadata
- Authors
- Busti, F., Marchi, G., Ugolini, S., Castagna, A., & Girelli, D.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2018-09-30
- Volume
- 11
- Issue
- 4
- Pages
- 94
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2893095850
- Cited by
- 165
- References
- 14
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.